Hadar Ilan 4

What Happened Hadar Ilan, Chairman, CEO and a director of Silexion Therapeutics Corp (SLXN), was granted 10,000 fully vested restricted share units (RSUs) on June 4, 2026 that were immediately settled for 10,000 ordinary shares. The reported acquisition price is $0.00 (no cash paid). After this settlement, Ilan beneficially owns 16,547 ordinary shares in total (6,547 prior to the grant plus the 10,000 shares from the RSU settlement).

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (filed within the standard 2-business-day window).
• Grant type/code: A (Award/Grant) — fully vested RSUs immediately settled for shares (per footnote).
• Shares acquired: 10,000 ordinary shares at $0.00 reported price; total reported shares owned after transaction: 16,547.
• Option holdings (adjusted for reverse split): 96 options to purchase 96 ordinary shares at an exercise price of $9,077.10 per share (adjustment due to 1-for-10 reverse split).
• Board approval: Grant was approved by the issuer’s board of directors (per footnote).
• Reverse split: A 1-for-10 reverse share split took effect May 28, 2026 and adjusted previously reported share and option counts/prices.

Context This was a compensation-related award (RSUs) settled immediately into shares for services as an officer, not an open-market purchase or sale. Such awards are routine forms of executive compensation and do not, by themselves, indicate a buy or sell signal. The option holdings were adjusted solely due to the issuer’s reverse split; the quoted exercise price reflects that adjustment.